ID   KPCB_HUMAN              Reviewed;         671 AA.
AC   P05771; C5IFJ8; D3DWF5; O43744; P05127; Q15138; Q93060; Q9UE49; Q9UE50;
AC   Q9UEH8; Q9UJ30; Q9UJ33;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   12-OCT-2022, entry version 254.
DE   RecName: Full=Protein kinase C beta type;
DE            Short=PKC-B;
DE            Short=PKC-beta;
DE            EC=2.7.11.13 {ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25982116};
GN   Name=PRKCB; Synonyms=PKCB, PRKCB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-II).
RX   PubMed=3755548; DOI=10.1126/science.3755548;
RA   Coussens L., Parker P.J., Rhee L., Yang-Feng T.L., Chen E.,
RA   Waterfield M.D., Francke U., Ullrich A.;
RT   "Multiple, distinct forms of bovine and human protein kinase C suggest
RT   diversity in cellular signaling pathways.";
RL   Science 233:859-866(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA-I AND BETA-II).
RX   PubMed=3666134; DOI=10.1016/0014-5793(87)80524-0;
RA   Kubo K., Ohno S., Suzuki K.;
RT   "Primary structures of human protein kinase C beta I and beta II differ
RT   only in their C-terminal sequences.";
RL   FEBS Lett. 223:138-142(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2009) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10493829; DOI=10.1006/geno.1999.5927;
RA   Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R., Fuhrmann J.,
RA   Mason T., Crosby M.L., Barnstead M., Cronin L., Mays A.D., Cao Y., Xu R.X.,
RA   Kang H.-L., Mitchell S., Eichler E.E., Harris P.C., Venter J.C.,
RA   Adams M.D.;
RT   "Genome duplications and other features in 12 Mb of DNA sequence from human
RT   chromosome 16p and 16q.";
RL   Genomics 60:295-308(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hippocampus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-69.
RX   PubMed=7880442; DOI=10.1089/dna.1995.14.213;
RA   Mahajna J., King P., Parker P., Haley J.;
RT   "Autoregulation of cloned human protein kinase C beta and gamma gene
RT   promoters in U937 cells.";
RL   DNA Cell Biol. 14:213-222(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-58.
RX   PubMed=1556124; DOI=10.1016/s0021-9258(18)42675-0;
RA   Niino Y.S., Ohno S., Suzuki K.;
RT   "Positive and negative regulation of the transcription of the human protein
RT   kinase C beta gene.";
RL   J. Biol. Chem. 267:6158-6163(1992).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57.
RX   PubMed=1400396; DOI=10.1016/s0021-9258(19)36758-4;
RA   Obeid L.M., Blobe G.C., Karolak L.A., Hannun Y.A.;
RT   "Cloning and characterization of the major promoter of the human protein
RT   kinase C beta gene. Regulation by phorbol esters.";
RL   J. Biol. Chem. 267:20804-20810(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-19, AND ACETYLATION AT ALA-2.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 97-176.
RA   Greenham J.A., Adams M.D., Doggett N.A., Mole S.E.;
RT   "The genomic structure of the human protein kinase C beta gene (PRKCB).";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 609-671.
RC   TISSUE=Fetal brain;
RX   PubMed=3677994; DOI=10.1089/dna.1987.6.389;
RA   Coussens L., Rhee L., Parker P.J., Ullrich A.;
RT   "Alternative splicing increases the diversity of the human protein kinase C
RT   family.";
RL   DNA 6:389-394(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 622-671.
RX   PubMed=3658678; DOI=10.1093/nar/15.17.7179;
RA   Kubo K., Ohno S., Suzuki K.;
RT   "Nucleotide sequence of the 3' portion of a human gene for protein kinase C
RT   beta-I/beta-II.";
RL   Nucleic Acids Res. 15:7179-7180(1987).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF BTK.
RX   PubMed=11598012; DOI=10.1093/emboj/20.20.5692;
RA   Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M.,
RA   Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N.,
RA   Rawlings D.J.;
RT   "PKCbeta modulates antigen receptor signaling via regulation of Btk
RT   membrane localization.";
RL   EMBO J. 20:5692-5702(2001).
RN   [15]
RP   ACTIVITY REGULATION.
RX   PubMed=16103100; DOI=10.1158/0008-5472.can-05-0071;
RA   Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L.,
RA   Bailey S.N., Banks C., Capen A., Goode R., Lewis J.E., Sams L., Huss K.L.,
RA   Campbell R.M., Iversen P.W., Neubauer B.L., Brown T.J., Musib L.,
RA   Geeganage S., Thornton D.;
RT   "The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl),
RT   suppresses signaling through the AKT pathway, induces apoptosis, and
RT   suppresses growth of human colon cancer and glioblastoma xenografts.";
RL   Cancer Res. 65:7462-7469(2005).
RN   [16]
RP   INTERACTION WITH PHLPP1 AND PHLPP2.
RX   PubMed=18162466; DOI=10.1074/jbc.m707319200;
RA   Gao T., Brognard J., Newton A.C.;
RT   "The phosphatase PHLPP controls the cellular levels of protein kinase C.";
RL   J. Biol. Chem. 283:6300-6311(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [18]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.m808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-504, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM BETA-II), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   FUNCTION IN HISTONE H3 PHOSPHORYLATION, CATALYTIC ACTIVITY, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH KDM1A; PKN1 AND AR.
RX   PubMed=20228790; DOI=10.1038/nature08839;
RA   Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N.,
RA   Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N.,
RA   Beisenherz-Huss C., Gunther T., Buettner R., Schule R.;
RT   "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at
RT   histone H3K4.";
RL   Nature 464:792-796(2010).
RN   [21]
RP   REVIEW ON FUNCTION.
RX   PubMed=12417015; DOI=10.1093/oxfordjournals.jbchem.a003273;
RA   Kawakami T., Kawakami Y., Kitaura J.;
RT   "Protein kinase C beta (PKC beta): normal functions and diseases.";
RL   J. Biochem. 132:677-682(2002).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=20186491; DOI=10.1007/s11154-010-9134-4;
RA   Tabit C.E., Chung W.B., Hamburg N.M., Vita J.A.;
RT   "Endothelial dysfunction in diabetes mellitus: molecular mechanisms and
RT   clinical implications.";
RL   Rev. Endocr. Metab. Disord. 11:61-74(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; THR-17; SER-206; SER-311;
RP   THR-314 AND THR-642, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM
RP   BETA-II), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=25982116; DOI=10.1016/j.molcel.2015.04.015;
RA   Lee E.E., Ma J., Sacharidou A., Mi W., Salato V.K., Nguyen N., Jiang Y.,
RA   Pascual J.M., North P.E., Shaul P.W., Mettlen M., Wang R.C.;
RT   "A protein kinase C phosphorylation motif in GLUT1 affects glucose
RT   transport and is mutated in GLUT1 deficiency syndrome.";
RL   Mol. Cell 58:845-853(2015).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 321-660 IN COMPLEX WITH INHIBITOR,
RP   AND PHOSPHORYLATION AT THR-500; THR-642 AND SER-661.
RX   PubMed=17115692; DOI=10.1021/bi061128h;
RA   Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B., Nonomiya J.,
RA   Grant S.;
RT   "Structure of the catalytic domain of human protein kinase C beta II
RT   complexed with a bisindolylmaleimide inhibitor.";
RL   Biochemistry 45:13970-13981(2006).
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-144; MET-496 AND HIS-588.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)-
CC       dependent serine/threonine-protein kinase involved in various cellular
CC       processes such as regulation of the B-cell receptor (BCR) signalosome,
CC       oxidative stress-induced apoptosis, androgen receptor-dependent
CC       transcription regulation, insulin signaling and endothelial cells
CC       proliferation. Plays a key role in B-cell activation by regulating BCR-
CC       induced NF-kappa-B activation. Mediates the activation of the canonical
CC       NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1
CC       at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces
CC       CARD11/CARMA1 association with lipid rafts and recruitment of the
CC       BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK
CC       complex, resulting in nuclear translocation and activation of NFKB1.
CC       Plays a direct role in the negative feedback regulation of the BCR
CC       signaling, by down-modulating BTK function via direct phosphorylation
CC       of BTK at 'Ser-180', which results in the alteration of BTK plasma
CC       membrane localization and in turn inhibition of BTK activity
CC       (PubMed:11598012). Involved in apoptosis following oxidative damage: in
CC       case of oxidative conditions, specifically phosphorylates 'Ser-36' of
CC       isoform p66Shc of SHC1, leading to mitochondrial accumulation of
CC       p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts
CC       as a coactivator of androgen receptor (AR)-dependent transcription, by
CC       being recruited to AR target genes and specifically mediating
CC       phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for
CC       epigenetic transcriptional activation that prevents demethylation of
CC       histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A (PubMed:20228790). In insulin
CC       signaling, may function downstream of IRS1 in muscle cells and mediate
CC       insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling
CC       cascade. Participates in the regulation of glucose transport in
CC       adipocytes by negatively modulating the insulin-stimulated
CC       translocation of the glucose transporter SLC2A4/GLUT4. Phosphorylates
CC       SLC2A1/GLUT1, promoting glucose uptake by SLC2A1/GLUT1
CC       (PubMed:25982116). Under high glucose in pancreatic beta-cells, is
CC       probably involved in the inhibition of the insulin gene transcription,
CC       via regulation of MYC expression. In endothelial cells, activation of
CC       PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced
CC       cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide
CC       synthase (NOS3/eNOS) regulation by insulin, which causes endothelial
CC       dysfunction. Also involved in triglyceride homeostasis (By similarity).
CC       Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN,
CC       activating transcription (PubMed:19176525).
CC       {ECO:0000250|UniProtKB:P68404, ECO:0000269|PubMed:11598012,
CC       ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:20228790,
CC       ECO:0000269|PubMed:25982116}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC         Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25982116};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:20228790, ECO:0000269|PubMed:25982116};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13; Evidence={ECO:0000269|PubMed:20228790};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000269|PubMed:20228790};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00041};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000250|UniProtKB:P68403};
CC   -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and
CC       PRKCG) are activated by calcium and diacylglycerol (DAG) in the
CC       presence of phosphatidylserine. Three specific sites; Thr-500
CC       (activation loop of the kinase domain), Thr-642 (turn motif) and Ser-
CC       661 (hydrophobic region), need to be phosphorylated for its full
CC       activation. Specifically inhibited by enzastaurin (LY317615).
CC       {ECO:0000269|PubMed:16103100}.
CC   -!- SUBUNIT: Interacts with PDK1 (By similarity). Interacts in vitro with
CC       PRKCBP1. Interacts with PHLPP1 and PHLPP2; both proteins mediate its
CC       dephosphorylation. Interacts with KDM1A/LSD1, PKN1 and AR.
CC       {ECO:0000250, ECO:0000269|PubMed:17115692, ECO:0000269|PubMed:18162466,
CC       ECO:0000269|PubMed:20228790}.
CC   -!- INTERACTION:
CC       P05771; Q8NEM2: SHCBP1; NbExp=3; IntAct=EBI-706216, EBI-744700;
CC       P05771; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-706216, EBI-717399;
CC       P05771-1; O60341-1: KDM1A; NbExp=2; IntAct=EBI-5774492, EBI-15599570;
CC       P05771-2; Q6DHV7-2: ADAL; NbExp=3; IntAct=EBI-5774511, EBI-18899653;
CC       P05771-2; Q9UQM7: CAMK2A; NbExp=3; IntAct=EBI-5774511, EBI-1383687;
CC       P05771-2; Q6ZQX7-4: LIAT1; NbExp=3; IntAct=EBI-5774511, EBI-25830459;
CC       P05771-2; O60346: PHLPP1; NbExp=5; IntAct=EBI-5774511, EBI-2511516;
CC       P05771-2; Q6ZVD8: PHLPP2; NbExp=2; IntAct=EBI-5774511, EBI-2511496;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000269|PubMed:20228790}. Membrane {ECO:0000250}; Peripheral
CC       membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Beta-I; Synonyms=PRKCB1;
CC         IsoId=P05771-1; Sequence=Displayed;
CC       Name=Beta-II; Synonyms=PRKCB2;
CC         IsoId=P05771-2; Sequence=VSP_004738;
CC   -!- PTM: Phosphorylation on Thr-500 within the activation loop renders it
CC       competent to autophosphorylate. Subsequent autophosphorylation of Thr-
CC       642 maintains catalytic competence, and autophosphorylation on Ser-661
CC       appears to release the kinase into the cytosol. Autophosphorylation on
CC       other sites i.e. in the N-terminal and hinge regions have no effect on
CC       enzyme activity. Phosphorylation at Tyr-662 by SYK induces binding with
CC       GRB2 and contributes to the activation of MAPK/ERK signaling cascade
CC       (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prkcb1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M13975; AAA60095.1; -; mRNA.
DR   EMBL; X06318; CAA29634.1; -; mRNA.
DR   EMBL; X07109; CAA30130.1; -; mRNA.
DR   EMBL; FJ907246; ACS14045.1; -; Genomic_DNA.
DR   EMBL; AC130454; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC002299; AAB97933.1; -; Genomic_DNA.
DR   EMBL; AC002299; AAB97934.1; -; Genomic_DNA.
DR   EMBL; CH471145; EAW55797.1; -; Genomic_DNA.
DR   EMBL; CH471145; EAW55798.1; -; Genomic_DNA.
DR   EMBL; BC036472; AAH36472.1; -; mRNA.
DR   EMBL; X62532; CAA44393.1; -; Genomic_DNA.
DR   EMBL; S47311; AAD13852.1; -; Genomic_DNA.
DR   EMBL; D10022; BAA00912.1; -; Genomic_DNA.
DR   EMBL; AJ002799; CAA05725.1; -; Genomic_DNA.
DR   EMBL; AJ002800; CAA05725.1; JOINED; Genomic_DNA.
DR   EMBL; M18254; AAA60096.1; -; Genomic_DNA.
DR   EMBL; M18255; AAA60097.1; -; Genomic_DNA.
DR   EMBL; X05972; CAA29396.1; -; Genomic_DNA.
DR   EMBL; X05971; CAA29395.1; -; Genomic_DNA.
DR   CCDS; CCDS10618.1; -. [P05771-1]
DR   CCDS; CCDS10619.1; -. [P05771-2]
DR   PIR; B24664; KIHUC2.
DR   PIR; S00159; KIHUC1.
DR   RefSeq; NP_002729.2; NM_002738.6. [P05771-2]
DR   RefSeq; NP_997700.1; NM_212535.2. [P05771-1]
DR   PDB; 2I0E; X-ray; 2.60 A; A/B=321-671.
DR   PDBsum; 2I0E; -.
DR   AlphaFoldDB; P05771; -.
DR   SMR; P05771; -.
DR   BioGRID; 111565; 196.
DR   DIP; DIP-34187N; -.
DR   IntAct; P05771; 144.
DR   MINT; P05771; -.
DR   STRING; 9606.ENSP00000305355; -.
DR   BindingDB; P05771; -.
DR   ChEMBL; CHEMBL3045; -.
DR   DrugBank; DB14001; alpha-Tocopherol succinate.
DR   DrugBank; DB09096; Benzoyl peroxide.
DR   DrugBank; DB08862; Cholecystokinin.
DR   DrugBank; DB14002; D-alpha-Tocopherol acetate.
DR   DrugBank; DB08846; Ellagic acid.
DR   DrugBank; DB06486; Enzastaurin.
DR   DrugBank; DB01738; Phosphorylcolamine.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00163; Vitamin E.
DR   DrugCentral; P05771; -.
DR   GuidetoPHARMACOLOGY; 1483; -.
DR   TCDB; 8.A.104.1.4; the 5'-amp-activated protein kinase (ampk) family.
DR   iPTMnet; P05771; -.
DR   MetOSite; P05771; -.
DR   PhosphoSitePlus; P05771; -.
DR   BioMuta; PRKCB; -.
DR   DMDM; 20141488; -.
DR   CPTAC; CPTAC-1338; -.
DR   EPD; P05771; -.
DR   jPOST; P05771; -.
DR   MassIVE; P05771; -.
DR   MaxQB; P05771; -.
DR   PaxDb; P05771; -.
DR   PeptideAtlas; P05771; -.
DR   PRIDE; P05771; -.
DR   ProteomicsDB; 51855; -. [P05771-1]
DR   ProteomicsDB; 51856; -. [P05771-2]
DR   Antibodypedia; 3547; 897 antibodies from 45 providers.
DR   DNASU; 5579; -.
DR   Ensembl; ENST00000321728.12; ENSP00000318315.7; ENSG00000166501.14. [P05771-1]
DR   Ensembl; ENST00000643927.1; ENSP00000496129.1; ENSG00000166501.14. [P05771-2]
DR   GeneID; 5579; -.
DR   KEGG; hsa:5579; -.
DR   MANE-Select; ENST00000643927.1; ENSP00000496129.1; NM_002738.7; NP_002729.2. [P05771-2]
DR   UCSC; uc002dmd.4; human. [P05771-1]
DR   CTD; 5579; -.
DR   DisGeNET; 5579; -.
DR   GeneCards; PRKCB; -.
DR   HGNC; HGNC:9395; PRKCB.
DR   HPA; ENSG00000166501; Tissue enhanced (brain, lymphoid tissue).
DR   MIM; 176970; gene.
DR   neXtProt; NX_P05771; -.
DR   OpenTargets; ENSG00000166501; -.
DR   PharmGKB; PA33761; -.
DR   VEuPathDB; HostDB:ENSG00000166501; -.
DR   eggNOG; KOG0696; Eukaryota.
DR   GeneTree; ENSGT00940000155217; -.
DR   HOGENOM; CLU_000288_54_2_1; -.
DR   InParanoid; P05771; -.
DR   OMA; YIAPEXA; -.
DR   OrthoDB; 614710at2759; -.
DR   PhylomeDB; P05771; -.
DR   TreeFam; TF351133; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   PathwayCommons; P05771; -.
DR   Reactome; R-HSA-114516; Disinhibition of SNARE formation.
DR   Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-4419969; Depolymerisation of the Nuclear Lamina.
DR   Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+.
DR   Reactome; R-HSA-8939246; RUNX1 regulates transcription of genes involved in differentiation of myeloid cells.
DR   SABIO-RK; P05771; -.
DR   SignaLink; P05771; -.
DR   SIGNOR; P05771; -.
DR   BioGRID-ORCS; 5579; 14 hits in 1113 CRISPR screens.
DR   ChiTaRS; PRKCB; human.
DR   EvolutionaryTrace; P05771; -.
DR   GeneWiki; PRKCB1; -.
DR   GenomeRNAi; 5579; -.
DR   Pharos; P05771; Tchem.
DR   PRO; PR:P05771; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P05771; protein.
DR   Bgee; ENSG00000166501; Expressed in middle temporal gyrus and 187 other tissues.
DR   ExpressionAtlas; P05771; baseline and differential.
DR   Genevisible; P05771; HS.
DR   GO; GO:0044305; C:calyx of Held; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0099523; C:presynaptic cytosol; IEA:Ensembl.
DR   GO; GO:0008091; C:spectrin; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005246; F:calcium channel regulator activity; IEA:Ensembl.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0035403; F:histone kinase activity (H3-T6 specific); IDA:UniProtKB.
DR   GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB.
DR   GO; GO:0030374; F:nuclear receptor coactivator activity; IMP:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; IDA:UniProtKB.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0042113; P:B cell activation; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0042953; P:lipoprotein transport; TAS:BHF-UCL.
DR   GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome.
DR   GO; GO:0010829; P:negative regulation of glucose transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0010827; P:regulation of glucose transmembrane transport; IDA:UniProtKB.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05616; STKc_cPKC_beta; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR034664; cPKC-beta.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative splicing;
KW   Apoptosis; ATP-binding; Calcium; Chromatin regulator; Cytoplasm;
KW   Direct protein sequencing; Immunity; Kinase; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801"
FT   CHAIN           2..671
FT                   /note="Protein kinase C beta type"
FT                   /id="PRO_0000055684"
FT   DOMAIN          158..275
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          342..600
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          601..671
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ZN_FING         36..86
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         101..151
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          311..330
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          614..635
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        315..330
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        614..633
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        466
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         186
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         193
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         247
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         251
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         252
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   BINDING         348..356
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         371
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|PubMed:12665801"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         16
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255"
FT   MOD_RES         17
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         206
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         250
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         314
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         324
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255"
FT   MOD_RES         500
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000305|PubMed:17115692"
FT   MOD_RES         504
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         635
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P68403"
FT   MOD_RES         642
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17115692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         661
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17115692"
FT   MOD_RES         662
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:P68404"
FT   VAR_SEQ         622..671
FT                   /note="RDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV
FT                   -> CGRNAENFDRFFTRHPPVLTPPDQEVIRNIDQSEFEGFSFVNSEFLKPEVKS (in
FT                   isoform Beta-II)"
FT                   /evidence="ECO:0000303|PubMed:3666134,
FT                   ECO:0000303|PubMed:3755548"
FT                   /id="VSP_004738"
FT   VARIANT         144
FT                   /note="V -> M (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs764534677)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042304"
FT   VARIANT         496
FT                   /note="V -> M (in a glioblastoma multiforme sample; somatic
FT                   mutation; dbSNP:rs1466858740)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042305"
FT   VARIANT         588
FT                   /note="P -> H (in dbSNP:rs35631544)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042306"
FT   CONFLICT        69
FT                   /note="V -> G (in Ref. 7; CAA44393)"
FT                   /evidence="ECO:0000305"
FT   STRAND          342..351
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   STRAND          354..361
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   STRAND          364..374
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           375..380
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           384..394
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   STRAND          406..411
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   STRAND          413..421
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           428..435
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           440..459
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           469..471
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   STRAND          472..474
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   STRAND          480..482
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           505..507
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           510..513
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           521..536
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           546..555
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           566..575
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           590..595
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           598..600
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           605..609
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           629..636
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   HELIX           646..651
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   TURN            654..657
FT                   /evidence="ECO:0007829|PDB:2I0E"
FT   MOD_RES         P05771-2:641
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         P05771-2:660
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:24275569"
SQ   SEQUENCE   671 AA;  76869 MW;  3937E7B667108C68 CRC64;
     MADPAAGPPP SEGEESTVRF ARKGALRQKN VHEVKNHKFT ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPASDDPRS KHKFKIHTYS SPTFCDHCGS
     LLYGLIHQGM KCDTCMMNVH KRCVMNVPSL CGTDHTERRG RIYIQAHIDR DVLIVLVRDA
     KNLVPMDPNG LSDPYVKLKL IPDPKSESKQ KTKTIKCSLN PEWNETFRFQ LKESDKDRRL
     SVEIWDWDLT SRNDFMGSLS FGISELQKAS VDGWFKLLSQ EEGEYFNVPV PPEGSEANEE
     LRQKFERAKI SQGTKVPEEK TTNTVSKFDN NGNRDRMKLT DFNFLMVLGK GSFGKVMLSE
     RKGTDELYAV KILKKDVVIQ DDDVECTMVE KRVLALPGKP PFLTQLHSCF QTMDRLYFVM
     EYVNGGDLMY HIQQVGRFKE PHAVFYAAEI AIGLFFLQSK GIIYRDLKLD NVMLDSEGHI
     KIADFGMCKE NIWDGVTTKT FCGTPDYIAP EIIAYQPYGK SVDWWAFGVL LYEMLAGQAP
     FEGEDEDELF QSIMEHNVAY PKSMSKEAVA ICKGLMTKHP GKRLGCGPEG ERDIKEHAFF
     RYIDWEKLER KEIQPPYKPK ARDKRDTSNF DKEFTRQPVE LTPTDKLFIM NLDQNEFAGF
     SYTNPEFVIN V
//
